Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor
about
sameAs
The discriminative stimulus effects of dopamine D2- and D3-preferring agonists in ratsSide effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacologyPharmacology of Ultrasonic Vocalizations in adult Rats: Significance, Call Classification and Neural SubstrateUpdate on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor AntagonismRotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptorsLSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT(2A) receptor.Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study.Regulation of dopaminergic function: an [18F]-DOPA PET apomorphine challenge study in humans.Cabergoline decreases alcohol drinking and seeking behaviors via glial cell line-derived neurotrophic factor.In vitro models: research in physiology and pharmacology of the lower urinary tract.GDNF--a potential target to treat addiction.Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.Self-administration of agonists selective for dopamine D2, D3, and D4 receptors by rhesus monkeys.Uncertainty about mapping future actions into rewards may underlie performance on multiple measures of impulsivity in behavioral addiction: evidence from Parkinson's disease.Possible sites of therapeutic action in restless legs syndrome: focus on dopamine and α2δ ligands.Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson's disease.Revision of the classical dopamine D2 agonist pharmacophore based on an integrated medicinal chemistry, homology modelling and computational docking approach.Recruitment of beta-arrestin2 to the dopamine D2 receptor: insights into anti-psychotic and anti-parkinsonian drug receptor signaling.Parkinson's disease: genetics and beyond.Effects in vitro and in vivo by apomorphine in the rat corpus cavernosum.Pergolide mesylate can improve sexual dysfunction in patients with Parkinson's disease: the results of an open, prospective, 6-month follow-up.Effect of Hallucinogens on Unconditioned Behavior.The effect of terguride in carbon tetrachloride-induced liver fibrosis in rat.Comparative effects of the dopaminergic agonists piribedil and bromocriptine in three different memory paradigms in rodents.The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.Targeting hypersensitive corticostriatal terminals in restless legs syndrome.Ropinirole and Pramipexole Promote Structural Plasticity in Human iPSC-Derived Dopaminergic Neurons via BDNF and mTOR Signaling.Targeting the intracellular signaling "STOP" and "GO" pathways for the treatment of alcohol use disorders.
P2860
Q24631461-2988DFCD-3B31-46BE-92C6-DD702D5789E3Q26738349-020AC208-A3C5-40E3-B629-EF15DA883BD6Q26786506-13F5E26A-CC8C-4A63-95C0-3BF4D8D6445AQ28084069-4E68EB7B-1D68-40AE-A43D-6C3E3ED8586EQ28250152-5B5777E2-D6CA-438C-AF16-DE769F8B9687Q30484494-8DE87AAE-12FD-4F6D-965C-8F9C0B066F76Q33465315-3F7AC6B5-94C3-4C9B-BC61-980B760B1584Q33707670-BC6AAC3D-DCFA-40A1-B1A3-F314481777A3Q33954437-F478C262-7004-4663-9F94-1BBCC03E0760Q36390257-E103E754-F14D-4948-92B2-1464C07FF25EQ36928841-6CB0EAF1-4B12-4F66-B5DF-23544A73FE43Q37030669-5C720131-E728-425E-A05F-72F54C94C1B4Q37410481-560AF448-214C-4C60-A23C-2465B3852D0DQ37604101-304BF260-BE22-4380-BED2-AEB1A4A678E7Q37895053-454B2D69-7F01-4E1A-B92C-FAE34B79D110Q38155589-1502DCAD-A659-4939-A7F8-7DF2D55BA6A2Q38233283-0F1D9D27-80CC-431E-B6B6-1F9C37D19F98Q39377323-C0C91F5A-E28A-4B05-938E-8F1EC42D853BQ39416222-A7507383-74C0-43A3-A690-1AB0DF5D3D2AQ42036250-E86A6C86-0935-4D7B-83C7-6A2E321E4C5BQ44981822-BF625B77-0765-463B-9C98-7631A732ECABQ45279141-33FF4171-D802-4415-AE8B-B702F46A4E2BQ46429020-FCBFB45B-3AEB-4028-890D-40EB86D05BDDQ46727000-4AAEB3F8-8410-4399-9C06-8428F8D9B12AQ46789074-1DD19F72-E6F2-4D84-B157-3416C2D423D8Q47752902-26611B44-75ED-4088-AA19-B0DB4A48D741Q47952336-A84E5794-C076-419A-9558-594920E80217Q52727018-64F8472F-123B-4ABC-B235-2E990F5BD06CQ55133068-8BE5968F-DB19-43B8-8D7B-05BE27BCF7A9
P2860
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Differential actions of antipa ...... alpha(1)/alpha(2)-adrenoceptor
@ast
Differential actions of antipa ...... alpha(1)/alpha(2)-adrenoceptor
@en
Differential actions of antipa ...... alpha(1)/alpha(2)-adrenoceptor
@nl
type
label
Differential actions of antipa ...... alpha(1)/alpha(2)-adrenoceptor
@ast
Differential actions of antipa ...... alpha(1)/alpha(2)-adrenoceptor
@en
Differential actions of antipa ...... alpha(1)/alpha(2)-adrenoceptor
@nl
prefLabel
Differential actions of antipa ...... alpha(1)/alpha(2)-adrenoceptor
@ast
Differential actions of antipa ...... alpha(1)/alpha(2)-adrenoceptor
@en
Differential actions of antipa ...... alpha(1)/alpha(2)-adrenoceptor
@nl
P2093
P356
P1476
Differential actions of antipa ...... alpha(1)/alpha(2)-adrenoceptor
@en
P2093
Didier Cussac
Frédéric De Ceuninck
Jean-Paul Nicolas
Mark J Millan
Valérie Audinot
P304
P356
10.1124/JPET.102.039875
P407
P577
2002-11-01T00:00:00Z